CAS: 1501-26-4; Methyl 5-Chloro-5-Oxopentanoate

相似化合物

35444-44-1 41624-92-4 1490-25-1

上下游产品

CAS号1501-27-5 戊二酸单乙酯 | CAS号108-55-4 戌二酸酐 | CAS号1119-40-0 戊二酸二甲酯 | CAS号110-94-1 戊二酸 | CAS号67-56-1 甲醇 | CAS号7719-09-7 氧氯化硫 | CAS号5962-88-9 环己烷戊酸 | CAS号3543-75-7 盐酸苯达莫司汀 | CAS号3637-14-7 5-羰基辛酸 | CAS号504-02-9 1,3-环己二酮 | CAS号22647-95-6 5-(4-溴苯基)戊酸 | CAS号198063-87-5 Methyl 3-[2-(4-... | CAS号18760-47-9 5-氧代-5-(2-噻吩)戊酸甲酯 | CAS号71160-24-2 [5S,12R]-二羟基-[6... | CAS号35333-26-7 5-(4-溴苯基)-5-氧代戊酸 | CAS号23422-25-5 methyl 5-[4-(5-...

📜戊二酸二甲酯置于氯化亚砜,Potassium Hydroxide体系中,用 甲醇 用作溶剂,化学反应 5.0H,反应生成4-氯甲酰基丁酸甲酯
参考文献:Design,Synthesis And Preliminary Bioactivity Studies Of 1,3,4-Thiadiazole Hydroxamic Acid Derivatives As Novel Histone Deacetylase Inhibitors
标题:Design,Synthesis And Preliminary Bioactivity Studies Of 1,3,4-Thiadiazole Hydroxamic Acid Derivatives As Novel Histone Deacetylase Inhibitors
摘要:Histone Deacetylase (Hdac) Inhibitors Have Emerged As A New Class Of Anticancer Agents,Targeting The Biological Processes Including Cell Cycle,Apoptosis And Differentiation. In The Present Study,A Series Of 1,3,4-Thiadiazole Based Hydroxamic Acids Were Developed As Potent Hdac Inhibitors. Some Of Them Showed Good Inhibitory Activity In Hdac Enzyme Assay And Potent Growth Inhibition In Some Tumor Cell Lines. Among Them,Compound 6I (Ic50 = 0.089 Mu M),Exhibited Better Inhibitory Effect Compared With Saha (Ic50 = 0.15 Mu M). (C) 2012 Elsevier Ltd. All Rights Reserved.
Doi:10.1016/j.Bmc.2012.04.032

专利信息

专利号:US-2010159540-A1
优先权日:2007-03-26
标题:Synthesis of resolvins and intermediates, compounds prepared thereby, and uses thereof
发明人：RODRIGUEZ ANA; SPUR BERND
权利人:RODRIGUEZ ANA; SPUR BERND
摘要:Methods are disclosed for the preparation of a new class of lipid mediators known as resolvins, with Resolvin D6 (4,17-dihydroxy-5E,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid) being exemplary. Also disclosed are methods for the efficient synthesis of key intermediates in the preparation of such resolvins, such as isotopically labeled ω-3 fatty acid metabolites, and derivatives and analogs thereof. The invention likewise extends to the intermediates so prepared, and to the resolvins prepared with their use.

专利号:US-6107495-A
优先权日:1996-07-24
标题:Thienylcyclohexane derivatives for thienylcyclohexyl synthesis
发明人：CAZAUX JEAN-BERNARD; DAFNIET MICHEL; KAMENKA JEAN-MARC; MANGINOT ERIC
权利人:EXPANSIA SA
摘要:PCT No. PCT/FR97/01382 Sec. 371 Date Jan. 19, 1999 Sec. 102(e) Date Jan. 19, 1999 PCT Filed Jul. 24, 1997 PCT Pub. No. WO98/03498 PCT Pub. Date Jan. 29, 1998Novel thienylcyclohexane derivatives of general formula (I), wherein R' is the 2-thienyl or 3-thienyl radical, R is the cyano radical or a radical of formula -C(O)A, and R2'' is a saturated or unsaturated optionally cyclic hydrocarbon radical, or an aryl radical, are disclosed. Methods for preparing said compounds, and the use thereof as novel industrial products for the synthesis of thienylcyclohexyl derivatives, are also disclosed.

专利号:US-5216005-A
优先权日:1989-03-15
标题:Immunosuppressive analogues and derivatives of succinylacetone
发明人：NITECKI DANUTE E; ALDWIN LOIS; LEVENSON COREY H; MORELAND MARGARET; BRAUDE IRWIN; MARK DAVID F; RAPOPORT HENRY
权利人:CETUS CORP
摘要:Succinylacetone derived or related medicaments and methods of synthesis of the same are shown wherein the medicaments consists of succinylacetonyl-proline-PEG, succinylacetonyl-NH-PEG, or compounds that have the formula: wherein n = 1-6 RIV = H, or alkyl and that have immunosuppressive activity both in vivo and in vitro based on their activities in cellular immunologic assays and adjuvant induced arthritis in rats, respectively.

专利号:US-5173482-A
优先权日:1989-03-15
标 题 :Immunosuppressive analogues and derivatives of succinylacetone
发明人：NITECKI DANUTE E; MORELAND MARGARET; ALDWIN LOIS; LEVENSON COREY H; BRAUDE IRWIN; MARK DAVID F; RAPOPORT HENRY
权利人:CETUS CORP
摘要:Succinylacetone derived or related medicaments and methods of synthesis of the same are shown wherein the medicaments consists of succinylacetonyl-proline-PEG, succinylacetonyl-NH-PEG, or compounds that have the formula: wherein n = 1-6 RIV = H, or alkyl and that have immunosuppressive activity both in vivo and in vitro based on their activities in cellular immunologic assays and adjuvant induced arthritis in rats, respectively.

专利号:US-4895872-A
优先权日:1989-03-15
标题:Immunosupressive analogues and derivatives of succinylacetone
发明人：NITECKI DANUTE E; MORELAND MARGARET; ALDWIN LOIS; LEVENSON COREY H; BRAUDE IRWIN; MARK DAVID F; RAPAPORT HENRY
权利人:CETUS CORP
摘要:Succinylacetone derived or related medicaments and methods of synthesis of the same are shown wherein the medicaments consists of succinylacetonyl-proline-PEG, succinylacetonyl-NH-PEG, or compounds that have the formula: wherein n = 1-6 RIV = H, or alkyl and that have immunosuppressive activity both in vivo and in vitro based on their activities in cellular immunologic assays and adjuvant induced arthritis in rats, respectively.

专利号:US-7442802-B2
优先权日:2002-06-27
标 题:Cyclooxygenase-2 selective inhibitors, compositions and methods of use
发明人：BANDARAGE UPUL K; EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; KHANAPURE SUBHASH P; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.